HIZENTRA®

FDA INDICATION: Primary immunodeficiency disease (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP) Package Insert

FORM: Liquid

DISTRIBUTOR: CSL Behring

ROUTE OF ADMINISTRATION: Subcutaneous

PH (AFTER RECONSTITUTION): 4.6–5.2

CONCENTRATION: 20%

IGA CONTENT: ≤50 μg/mL

% IGG: ≥98%

NA CONTENT: Trace amounts

DILUENT: N/A

OSMOLALITY (MOSM/L): 380 mOsmol/kg

INITIAL INFUSION RATE: Not for intravenous administration. Avoid injection into blood vessel. Injection sites: abdomen, thighs, upper arms, or lateral hip. Manufacturer recommends 15 mL volume per infusion site at a max rate of 50 mL/hr/site by infusion pump.

SUGAR CONTENT: No added sugars

SHELF LIFE: 30 months

STORAGE REQUIREMENTS: Store at room temperature up to 25°C (77°F). Do not freeze. Protect from light.

PATIENT SUPPORT/ASSISTANCE PROGRAMS: CSL Behring Patient Assistance Program, CSL Behring Assurance Program

OTHER WEBSITES: TreatingPI, IgIQ, hizentra.com